How has Tandem Diabetes Care's research and development expense changed year-over-year?

Tandem Diabetes Care's research and development expense decreased by 8.3% year-over-year, from $50.22M to $46.04M.

What is the long-term trend for Tandem Diabetes Care's research and development expense?

Over 3 years (2022 to 2025), Tandem Diabetes Care's research and development expense has grown at a 11.6% compound annual growth rate (CAGR), from $139.11M to $193.11M.

Tandem Diabetes Care TNDM Research and development expense

Research and development expense at other companies

MedtronicMDT

——

MannkindMNKD

——

Halozyme TherapeuticsHALO

——

Other financials

Income statement

See full

Revenue$247.2M+5.5%

Gross profit$136.8M+15.5%

Operating income-$17.4M+85.6%

Net income-$20.4M+84.4%

EPS (diluted)-$0.30+84.8%

Balance sheet

See full

Cash & equivalents$179.3M+235%

Total debt$734.7M+49.0%

Total equity$132.4M-14.7%

Total assets$1.2B+25.1%

Cash flow

See full

Operating cash flow$11.1M+160%

CapEx$6.3M+111%

Free cash flow$4.8M+123%

Valuation

See full

Market cap$1.03B-19.8%

Enterprise value$1.58B-8.5%

P/S1×-0.3×

Profitability

See full

Gross margin54.9%+2.7pp

Operating margin-8.2%-2.9pp

Net margin-9.2%-3.1pp

FCF margin-0.8%-0.4pp

Returns & leverage

See full

Return on equity-65.7%-14.7pp

Debt / equity5.5×+2.4×

Current ratio3.6×+1.3×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tandem Diabetes Care's research and development expense?: Tandem Diabetes Care (TNDM) reported research and development expense of $46.04M in Q1 2026.
How has Tandem Diabetes Care's research and development expense changed year-over-year?: Tandem Diabetes Care's research and development expense decreased by 8.3% year-over-year, from $50.22M to $46.04M.
What is the long-term trend for Tandem Diabetes Care's research and development expense?: Over 3 years (2022 to 2025), Tandem Diabetes Care's research and development expense has grown at a 11.6% compound annual growth rate (CAGR), from $139.11M to $193.11M.